PALATIN AND KING PHARMACEUTICALS BEGIN PT-141 STUDY

Palatin Technologies and King Pharmaceuticals have begun enrollment in a double-blind, placebo-controlled Phase IIb clinical trial of PT-141 in patients with female sexual arousal disorder (FSAD).

The primary objective of this pilot clinical trial is to evaluate the safety and efficacy of PT-141 in FSAD patients in the "at-home" environment.

The trial is designed to enroll approximately sixty women with a confirmed diagnosis of FSAD. The clinical trial entails a two- month treatment period and will be conducted at approximately ten clinical trial sites throughout the U.S.